<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298556</url>
  </required_header>
  <id_info>
    <org_study_id>GSS-13-0019</org_study_id>
    <nct_id>NCT02298556</nct_id>
  </id_info>
  <brief_title>An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes</brief_title>
  <acronym>HARVEST-TR</acronym>
  <official_title>A Prospective Noninterventional, Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Non-dihydropyridine Calcium Channel Blocker Single Pill Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MonitorCRO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the effectiveness of angiotensin-converting enzyme inhibitor and
      non-dihydropyridine calcium channel blocker single pill combination on systolic blood
      pressure (SBP) lowering in hypertensive patients with elevated heart rate and type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">March 8, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in systolic blood pressure</measure>
    <time_frame>from baseline to week 8</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in diastolic blood pressure (DBP)</measure>
    <time_frame>from baseline to week 8</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients achieving blood pressure ≤ 140 and/or 90 mmHg</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of responder patients (reduction of SBP ≥20 mmHg and/or DBP ≥10 mmHg)</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change of heart rate</measure>
    <time_frame>from baseline to week 8</time_frame>
    <description>beat/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between absolute change in blood pressure and absolute change in heart rate</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change in PR interval on electrocardiography</measure>
    <time_frame>from baseline to week 8</time_frame>
    <description>ms. The PR interval indicates &quot;atrioventricular conduction time&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change in HbA1c (if available)</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change in microalbuminuria (if available)</measure>
    <time_frame>from baseline to week 8</time_frame>
    <description>mg/mmol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of patients experiencing an adverse event including the nature of the adverse event/severe adverse event</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between physician's office and home blood pressure measurements (Difference in medians)</measure>
    <time_frame>from baseline to week 8</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure variability (daily or hourly) in home blood pressure measurement</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">270</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Hypertensive patients</arm_group_label>
    <description>Hypertensive patients with elevated heart rate and type 2 diabetes mellitus</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        State Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  ≥ 18 years old

          -  Has been already diagnosed with hypertension

          -  Has been already diagnosed with type 2 diabetes mellitus

          -  Started using angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium
             channel blocker single pill combination within a maximum of 1 week before enrolment

          -  Heart rate ≥70 beat per minute

        Exclusion Criteria:

          -  Pregnant or breast feeding female

          -  Current need to use any other antihypertensive drug(s) in addition to
             angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium channel
             blocker single pill combination

          -  Having any contraindication for angiotensin-converting enzyme inhibitor or
             non-dihydropyridine calcium channel blocker;

          -  Has been treated by any anti-hypertensive treatment(s) before angiotensin-converting
             enzyme inhibitor and non-dihydropyridine calcium channel blocker single pill
             combination

          -  Is currently participating in another clinical or non-clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enver Atalar, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University Faculty of Medicine Hospital Cardiology Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research facility ID ORG-001108</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001030</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yıldırım Beyazıt University Yenimahalle Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>6170</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001111</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001120</name>
      <address>
        <city>Aydın</city>
        <zip>09020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001119</name>
      <address>
        <city>Aydın</city>
        <zip>09100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001116</name>
      <address>
        <city>Balıkesir</city>
        <zip>10000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001112</name>
      <address>
        <city>Burdur</city>
        <zip>15300</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erzurum Regional Training and Research Hospital</name>
      <address>
        <city>Erzurum</city>
        <zip>25040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atatürk University Aziziye Research Hospital</name>
      <address>
        <city>Erzurum</city>
        <zip>25080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001118</name>
      <address>
        <city>İstanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakırköy Dr. Sadi Konuk Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001117</name>
      <address>
        <city>İstanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001125</name>
      <address>
        <city>İstanbul</city>
        <zip>34920</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001113</name>
      <address>
        <city>Karabük</city>
        <zip>78100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001110</name>
      <address>
        <city>Konya</city>
        <zip>42250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001115</name>
      <address>
        <city>Kırıkkale</city>
        <zip>71400</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001122</name>
      <address>
        <city>Trabzon</city>
        <zip>61800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uskudar PublicHospital</name>
      <address>
        <city>Uskudar</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yalova Public Hospital</name>
      <address>
        <city>Yalova</city>
        <zip>77000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001124</name>
      <address>
        <city>Zonguldak</city>
        <zip>67900</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001123</name>
      <address>
        <city>Çorum</city>
        <zip>19200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>ACE Inhibitors</keyword>
  <keyword>Calcium Channel Blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

